Introduction:
The 'from bench to clinic' story of cisplatin 1 has simulated the search for other transition metal anticancer complexes with improved features. In particular some group 8 organometallic complexes of iron, ruthenium and osmium show promising activity. 2, 3 For example, Jaouen et al. have designed ferricenium complexes which target hormone receptors in breast cancer cells, 4 certain Ru II arene complexes are active in vitro and in vivo, [5] [6] [7] , 8 and a few reports of anticancer active organometallic osmium complexes have recently appeared. [9] [10] [11] [12] [13] [14] [15] Osmium complexes are often considered to be relatively inert (a common characteristic of low-spin d 6 metal ions and especially 3 rd row transition metals). 16, 17 Organometallic Os II and Ru II arene complexes can adopt very similar threedimensional structures. For example, for the kinase inhibitors designed by Meggers et al. 18 , both osmium and ruthenium analogues are part of an inert scaffold that neatly fits into the active site of the enzyme and promotes specific outer-sphere contacts between groups on the ligands and the enzyme. There can also be intriguing differences between the chemical properties of organometallic Ru II The only recognised clinical use of osmium appears to be for synovectomy in arthritic patients in Scandinavia. [20] [21] [22] This involves the local administration of osmium tetroxide (OsO 4 ), usually considered to be a highly toxic compound. The lack of reports of long term side effects suggest that osmium itself can be biocompatible, although clearly this might be dependent on the exact nature of the compound administered. Osmium carbohydrate polymers (osmarins) have been also investigated as potential antiarthritic agents. 23 Recently, non-organometallic osmium(VI) complexes were reported to show anticancer activity in vivo. 12 We have also reported that certain half-sandwich organometallic iodido osmium phenylazopyridine arene complexes exhibit potent in vitro and in vivo anticancer activity, higher activity than the clinical drug cisplatin to a panel of cancer cell lines in vitro. 24, 25 Similar to Ru II , 26 we have found that the introduction of the strong π-acceptor azopyridine as a ligand in organometallic Os II complexes has a major effect on their chemical and biological properties.
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For Os II arene picolinate complexes, log P values correlate with cellular uptake, which
indicates that increased lipophilicity favours uptake by cancer cells, probably through a passive diffusion pathway, and results in an increase in anticancer activity. 27 However, increasing lipophilicity to improve anticancer activity can result in difficulties with clinical formulation and lower bioavailability 28 . Hence there is a need for rational design aimed at tuning lipophilicity while maintaining anticancer activity.
The goal of anticancer research programs is to identify novel, synthetically-feasible molecules that exhibit useful anticancer activity with minimal side-effects. One efficient approach is the study of bioisosterism, a term coined to describe the modification of biological activity by isosterism. [29] [30] [31] Here we report studies of a series of novel bioisosteres of Os II arene complexes containing chelated phenylazopyridines with various substitutents on the pyridine ring. We show that cellular reactive oxygen species (ROS) accumulate but do not lead to the death of cancer cells, suggesting a mechanism different from that for related complexes with an unsubstituted pyridine ring and a substitutent on the phenyl ring. In addition, it is found that down-regulation of the cellular GSH level results in lowering of anticancer activity, a property which has been found only for the anticancer drug taxol, which binds to tubulin in a GSHdependent manner.
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Results
Previously we reported the synthesis and cancer cell cytotoxicity of twelve osmium(II) phenylazopyridine complexes containing various substituents on the phenyl ring. 24 The least active compounds in this class contained unsubstituted phenyl rings. 24 In (26) were also determined by X-ray crystallography (Fig 1, Tables S1 and S2 ). All adopt the familiar halfsandwich 'piano-stool' geometry.
Stability and Hydrolysis.
We investigated the hydrolysis (aquation) of these azopyridine complexes since this is a potential mechanism for activation of halido osmium arene complexes in their interactions with biological targets such as DNA. 33 The aqueous behaviour of the highly active complex 9 [Os(η 6 -bip)(2-F-Azpy)I]PF 6 and moderately active complex 23 [Os(η 6 -bip)(3-Cl-Azpy)I]PF 6 was studied at 310 K.
The UV-Vis spectra, showed no change after 24 h, (Fig S1) indicating that complexes 9 and 23 remained stable and did not hydrolyze over that period, similar to the highly active azopyridine complexes containing unsubstituted pyridine rings that we reported previously. (Table 1A) . (1) Complexes containing iodide as the monodentate ligand have a higher activity compared to the chlorido complexes (Table 1B) .
(2) Biphenyl complexes are, in general, 10 times more active than p-cymene complexes (Table 1C) . (Table 1A) .
Partition Coefficients (Log P). Octanol/water partition coefficients (log P values)
provide a measure of the lipophilicity of compounds and are often a useful indication of the likely extent of drug uptake by cells. 34 We determined log P values for four iodido complexes 9 (2-F), 13 (2-Cl), 17 (2-Br), and 23 (3-Cl), and two chlorido complexes 19 (2-Br), and 25 (3-Cl), all biphenyl arene complexes, using the "shake tube method". The log P values for these complexes (Table S3) Table. S4). It is interesting that for 23 there is a very high percentage of osmium in the cytoskeleton, up to 43 % of the total cellular Os ( Fig S2) . Exposure of A2780 cells to 9 (1 μM) in the presence of the antioxidant thiol N-acetyl-L-cysteine (NAC, 50 μM) 39 gave no increase in ROS level compared to the control.
Detection of ROS in A2780 Cancer
However, for 9 (1 μM) with L-BSO (50 μM), the increase in ROS level was even higher than that for H 2 O 2 (50 μM). (Fig 5A) The increase of fluorescence over time after exposure of A2780 cells preloaded with DCFH-DA to 1 µM of 9, indicates that 9
causes a build-up of ROS inside A2780 cancer cells.
Relationship of Cytotoxicity to ROS.
In order to further investigate the possible involvement of ROS in the cytotoxicity of the phenylazopyridine osmium arene complexes studied here, we also investigated the combined effects of either complex 9 or 17 with the reductant NAC which can deplete ROS or with L-BSO which depletes glutathione levels and can lead to an increase in levels of ROS in cells.
The cytotoxicity assays showed that complex 9 (1 μM) in combination with the reductant (antioxidant) NAC (50 μM) did not increase the survival of A2780 cells compared to those treated with 9 alone for 24 h (Fig 5B) . This suggests that ROS are not implicated in cell death induced by complex 9. In contrast, combination treatment with the oxidant L-BSO, which resulted in an increase in the ROS level, blocked the anticancer activity.
The effect of combination treatment with the reductant (antioxidant) NAC (50 μM) on IC 50 values for complex 9 was investigated for both A2780 (ovarian) and A549 (lung) human cancer cell lines (Table 2 ). A2780 cells were treated with various concentrations of 9 or 17 together with NAC (50 μM). Combination treatment with NAC decreased the cytotoxicity of both 9 and 17, slightly. However, combination treatment with L-BSO raised the IC 50 values for 9 and 17 more than 10 times for A2780 cells. For the A549 cell line, the IC 50 value of 9 was raised from 1.8 µM to more than 100 µM, and for 17 the IC 50 values increased more than 70-fold (Table 2) .
Intriguingly, these data resemble those reported for the effects of combination treatment on the organic drug Paclitaxel (Taxol) which is in clinical use for the treatment of ovarian, breast and non-small cell lung cancer. Taxol is known to target tubulin in microtubules. The aim of the current work was to investigate the effects on anticancer activity of introducing substituents into the pyridine ring especially when the phenyl ring is left unsubstituted. We synthesised and characterized 32 novel organometallic osmium phenylazopyridine complexes (Chart 1). All the osmium complexes adopted the familiar piano-stool geometry in the crystalline state, with bond lengths and angles within the expected ranges. 24 Selected bond lengths and angles for these structures are listed in the supporting information (Table S2 ). For the iodido osmium complexes, the Os-C (arene) bond lengths are in the range of 2.172-2.284 Å, and the Os-I bond lengths from 2.7002-2.7063 Å (Table S2) -bip)(1-Cl-Azpy)Cl]PF 6 (7), the structure determined for a complex with an ortho pyridine substituent (Cl), Table S2 . 
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Remarkably electron-withdrawing substituents on the pyridine ring can give rise to highly potent complexes with IC 50 values in the nano-molar range (Table 1A and Fig. 2). The structure-activity relationships show that potency is higher for biphenyl versus p-cymene as the arene (Table 1C) , and for iodide compared to chloride as the monodenate ligand (Table 1B) . Biphenyl is a stronger π-acceptor than p-cymene (back-donation of electron density from Ru II ) whereas p-cym is the stronger electron donor. When Ru II arene complexes bind to DNA, the uncoordinated phenyl ring of bip can intercalate between DNA bases whereas DNA distortions caused by p-cymene are steric in origin. 42 The arene can also have a major effect on interactions with protein targets, as demonstrated for interactions between serum albumin and biphenyl and pcymene Ru II complexes. 43 The inertness of the most active complexes to hydrolysis suggests direct binding to DNA is not the major mechanism of action and that a novel target for these metal arene complexes is involved. This was also the conclusion from our recent work on Os II phenylazopyridine complexes containing unsubstituted pyridine and substitutions of the phenyl ring.
Reactive oxygen species (ROS) play important roles in regulating cell proliferation, death, and senescence, they can also play significant roles in the mechanism of action of anticancer agents. 44 We suggested previously that the cytotoxicity mechanism for osmium arene phenylazopyridine iodido complexes containing unsubstituted (R 1 -R 4 = H) pyridine rings and their ruthenium analogues is related to ROS generation. 26 However, the complexes investigated in the current work containing substituted pyridine rings do not appear to share a mechanism dependent to the formation of ROS.
Down-regulation of ROS by increasing intracellular GSH, does not block the anticancer activity of 9 and 17. It is also known that cisplatin resistance is partly related to an increase of GSH levels, 45 and the data for complexes 9 and 17 suggest that they have potential for the treatment of cisplatin-resistant tumours. 46 The mechanism of action of complexes 9 and 17 is GSH-dependent. L-buthionine sulfoximine (L-BSO) depletes intracellular glutathione levels by inhibiting the enzyme glutamylcysteine synthetase. L-BSO is on clinical trial for combination treatment with Melphalan, 47 and increases the cytotoxicity of a number of therapeutic agents, including cisplatin, especially towards resistant cancer cell lines. 48, 49 The only reported exception in which the L-BSO can block the cytotoxicity of a drug appears to be taxol. 32 Our report is apparently only the second in which a blocking of anticancer activity by L-BSO has been observed.
For the structure activity relationships, it is evident that when biphenyl is the arene and iodide is the monodentate ligand, the osmium complexes in this class show the highest anticancer activity towards A2780 cells, consistent with our previous work on phenylazopyridine complexes with unsubstituted pyridine rings. 24 In our previous work some chlorido complexes were found to be unstable in aqueous solution which resulted in low anticancer activity. 24, 40 Introducing biphenyl as the arene instead of p-
cymene not only provides a potential DNA intercalator but also increases the hydrophobicity for interaction with proteins which may contribute to the increased activity. 5, 50 Consideration of the substituents on the pyridine ring shows that changing from chloride at R 3 to fluoride causes the cellular accumulation of osmium to increase dramatically and is accompanied by an improvement in anticancer activity. The difference in the extent of cellular accumulation within this family may contribute to the observed variations in anticancer activity, as may interactions with targets (which may be proteins) . 50 To investigate whether there is a link between lipophilicity and anticancer activity for these complexes. The log P values were determined; they cover a broad range from -1.446 to 0.1330 (Table S3) . These values can be compared to those for the less lipophilic clinical Pt II drug cisplatin (log P = -2.36) 51 and to the Ru III drug NAMI-A . Hence there appears to be little correlation between lipophilicity (log P), and anticancer activity (Fig. 3 and Table. S3). The introduction of bioisosterism into the design has led to the discovery of compounds with different pharmaceutical properties, potential candidates for further pharmacokinetic studies.
The cell distribution studies showed a dramatic increase in accumulation of osmium in the membrane and particulate fraction of A2780 cells for 9 compared to 23, and 9 is more than 50 times more active than 23. Whether the critical target site is in the membrane and particulate fraction remains to be investigated further. However, to identify and determine the contribution of the individual binding sites is a complex task, for example, only ca. 1 % of Pt from intracellular cisplatin binds to its target, DNA, 53, 54 Further work is required to validate the target for this sub-family of osmium arene phenylazopyridine complexes.
Experimental section
Materials. [Os(η 6 -p-cym)Cl 2 ] 2 have been previously reported. 55 The synthesis of the phenylazopyridine ligands has been previously described. 26 The A2780 human with a Ruby CCD area detector using Mo Kα radiation. 56 Absorption corrections were applied using ABSPACK. The crystals were mounted in oil and held at 100(2) K with the Oxford Cryosystem Cryostream Cobra, except compound 7 for which data was collected at ambient temperature. The structures were solved by direct methods using SHELXS (TREF) with additional light atoms found by Fourier methods. Single crystals suitable for X-ray diffraction were obtained by crystallization from methanol solutions at 253 K. The details of the syntheses and characterizations are in the Supporting Information. The whole cell pellets were digested as described below. Firstly, 0.5 mL of freshly distilled 72% HNO 3 was added to each 1 mL cells pellets, and the samples were transferred into Wheaton V-Vials The vials were heated in an oven at 373 K for 16 h to digest the samples fully, allowed to cool, and then transferred to Falcon tubes. The vials were washed with double deionized water three times and diluted 10 times with double deionized water to obtain 6% HNO 3 sample solutions. A blank and the standards were loaded into the sample tray and were run from the lowest to the highest concentration in a 'no gas' mode, followed by the samples. 
Methods
